CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
- Status
- SUSPENDED
- Phase
- PHASE2
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE3
Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
FT538 in Subjects With Advanced Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
- Status
- UNKNOWN
- Phase
- PHASE2
Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
- Status
- TERMINATED
- Phase
- PHASE2
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
- Status
- TERMINATED
- Phase
- PHASE2
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
- Status
- TERMINATED
- Phase
- PHASE2
Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2